Modulation of cell-mediated immunity by lithium chloride. 1994

M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
Department of Immunology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.

Immunomodulation of cell-mediated immunity was studied in mice treated with either lithium chloride (LiCl), anti-CD8 monoclonal antibody or their combination. While 6-day LiCl treatment decreased the ability of their splenocytes to induce a local graft-versus-host reaction--anti-CD8 abolished this effect. The proliferative response of spleen cells from those three groups of mice to concanavalin A stimulation in vitro was significantly increased. The natural killer (NK) cell toxicity of the mice was decreased by over 43% after the 6-day LiCl treatment, but was x 2.5 higher then the control value after a longer 21-d treatment. These results indicate that the immunomodulatory capacity of lithium is dependent on the type of cell population studied, and on the schedule of administration.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D003433 Crosses, Genetic Deliberate breeding of two different individuals that results in offspring that carry part of the genetic material of each parent. The parent organisms must be genetically compatible and may be from different varieties or closely related species. Cross, Genetic,Genetic Cross,Genetic Crosses
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006087 Graft vs Host Reaction An immunological attack mounted by a graft against the host because of HISTOINCOMPATIBILITY when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE. HLA Sensitization,Human Leukocyte Antigen Sensitization,Sensitization, HLA
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
January 1975, Annals of the New York Academy of Sciences,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
June 2013, Endocrine, metabolic & immune disorders drug targets,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
March 2009, The Journal of organic chemistry,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
January 1987, Annals of the New York Academy of Sciences,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
January 1987, Czechoslovak medicine,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
March 1979, Cellular immunology,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
January 1987, Annals of the New York Academy of Sciences,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
May 1983, Life sciences,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
December 1980, Nature,
M Kubera, and M Bubak-Satora, and V Holan, and W Krol, and A Basta-Kaim, and A Roman, and A Skowron-Cendrzak, and J Shani
May 1995, Biochemical Society transactions,
Copied contents to your clipboard!